| Recruiting | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer NCT07423585 | Asrar Alahmadi | Phase 2 |
| Recruiting | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Canc NCT06769126 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Dur NCT06287775 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC NCT06672133 | Jinming Yu | Phase 3 |
| Recruiting | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation NCT06110572 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive S NCT05161533 | University of Washington | Phase 2 |
| Active Not Recruiting | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell NCT05353439 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer NCT05244239 | Emory University | Phase 1 |
| Completed | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial NCT05339022 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Can NCT05191797 | University of Washington | Phase 1 / Phase 2 |
| Recruiting | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung NCT04919382 | Dwight Owen | Phase 2 |
| Recruiting | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer NCT04696575 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lun NCT04560972 | City of Hope Medical Center | Phase 1 |
| Completed | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment NCT04631029 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive S NCT04402788 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-S NCT04728230 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker NCT04334941 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Rad NCT04155034 | SWOG Cancer Research Network | Phase 3 |
| Completed | Resiliency Among Older Adults Receiving Lung Cancer Treatment NCT04229381 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell C NCT03896503 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer NCT03995667 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage S NCT03830918 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small NCT03382561 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer NCT02899728 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-S NCT00453154 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |